Treatment setting, symptomatology, clinical course, severity degree and case-fatality rate in 536 adults over 50 years with laboratory-confirmed COVID-19 in Tarragona, Spain, March-June 2020
e202109115
Keywords:
Coronavirus, COVID-19, SARS-CoV-2, Symptoms, LethalityAbstract
Background: Population-based clinical data on COVID-19 is scarce. This study analyzed distinct clinical characteristics of COVID-19 and relationships with lethality among adults.
Methods: Retrospective cohort that included all population ≥50 years with a laboratory-confirmed COVID-19 in Tarragona, Spain, during 01/03/2020-30/06/2020. Treatment setting (outpatient/hospital/nursing-home), pre-existing comorbidities, signs/symptoms, clinical course, severity and lethality (death from any cause in-hospital or within the first 30-day after the diagnosis) were determined. Chi squared and Fisher’s test were used to compare percentages.
Results: Of the 536 overall cases (mean age: 74 years; 43.8% male), 150 (28%) were outpatient, 179 (33.4%) were hospitalised and 207 (38.6%) happened in nursing-home/social-health centres. The most prevalent symptoms were fever (57.9%), cough (49.8%), dyspnea (41.5%), general discomfort (36.2%), fatigue (24.4%), diarrhea (19.6%), myalgias (17.3%), headache (14.6%), confusion/lethargy (14.6%), thoracic pain (10%), anosmia (9.8%), disgeusia/ageusia (8.1%) and sore throat (7.7%). Global lethality was 23.1% (1.7% in 50-64 years vs 25.5% in 65-79 years vs 38.7% in ≥80 years, p<0.001; 26.8% in men vs 20.3% in women, p=0.075; 3.3% in outpatient vs 29.6% in hospitalised vs 31.9% in nursing-home/social-health centres, p<0.001). By symptomatology, maximum lethality was observed among patients with confusion/lethargy (77.6%) and minimum among those with ageusia/disgeusia (4.8%), anosmia (3.9%) or myalgias (1.1%). By pre-existing comorbidities, greater lethality happened among patients with neurologic (36.7%), renal (35.4%) and cardiac disease (35.3%).
Conclusions: There was a relatively great lethality of COVID-19 among the general population ≥50 years across the first epidemic wave in the study setting. Increasing age, male sex, nursing-home residence and several signs/symptoms and comorbidities were associated with higher mortality.
Downloads
References
World Health Organisation. WHO Coronavirus Disease (COVID-19) Dashboard. Disponible en: https://covid19.who.int/?gclid=EAIaIQobChMImdmz4eeO7wIVxvZRCh3rRQhlEAAYASAAEgIgjvD_BwE [Consultado 1/3/2021].
Gobierno de España. Ministerio de Sanidad. COVID-19 en España. Informes COVID-19. Disponible en: https://cnecovid.isciii.es/ [Consultado 1/3/2021].
Rodríguez-Molinero A, Gálvez-Barrón C, Miñarro A et al. Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients. PLoS One. 2020;15(10):e0239571.
Struyf T, Deeks JJ, Dinnes J et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020;7(7):CD013665.
Yang L, Jin J, Luo W, Gan Y, Chen B, Li W. Risk factors for predicting mortality of COVID-19 patients: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0243124.
Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020;383(18):1757-1766.
Michelen M, Jones N, Stavropoulou C; Oxford COVID-19 Evidence Service. In patients of COVID19, What are the symptoms and clinical features of mild and moderate case? Centre for Evidence-Based Medicine (CEBM) Oxford. 2020. Disponible en: https://www.cebm.net/covid-19/in-patients-of-covid-19-what-are-the-symptoms-and-clinical-features-of-mild-and-moderate-case/ [Consultado 25/2/2021].
Stokes EK, Zambrano LD, Anderson KN et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759-765.
Grant MC, Geoghegan L, Arbyn M et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020;15(6):e0234765.
Pijls BG, Jolani S, Atherley A et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11(1):e044640.
de Lusignan S, Dorward J, Correa A et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20(9):1034-42.
Mesas AE, Cavero-Redondo I, Álvarez-Bueno C et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. PLoS One. 2020;15(11):e0241742.
Wynants L, Van Calster B, Collins GS et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal [published correction appears in BMJ. 2020 Jun 3;369:m2204]. BMJ. 2020;369:m1328.
Vila-Córcoles Á, Ochoa-Gondar O, Torrente-Fraga C et al. Evaluación de la incidencia y perfil de riesgo de Covid-19 según comorbilidad previa en adultos ≥50 años del área de Tarragona. Rev Esp Salud Publica. 2020;94:e202006065.
Vila-Córcoles A, Ochoa-Gondar O, Satué-Gracia EM et al. Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain. BMJ Open. 2020;10(12):e041577.
Instituto de Estadística de Cataluña. IDESCAT. Disponible en: https://www.idescat.cat/?lang=es [Consultado 15/01/2021].
World Medical Association. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Disponible en: https://www.wma.net/policies-post/wmadeclaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
[Consultado 15/01/2021].
Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O et al. Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. BMC Public Health. 2010;10:25.
Generalitat de Catalunya. Subdirecció General de Vigilància i Resposta a Emergències de Salut Pública. Procediment d’actuació enfront de casos d’infecció pel nou coronavirus SARSCoV-2. Disponible en: https://canalsalut.gencat.cat/web/.content/_A-Z/C/coronavirus-2019-ncov/material-divulgatiu/procediment-actuacio-coronavirus.pdf [Consultado 15/01/2021].
Working group for the surveillance and control of COVID-19 in Spain. The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020. Euro Surveill. 2020;25(50):pii=2001431.
Docherty AB, Harrison EM, Green CA et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
Arons MM, Hatfield KM, Reddy SC et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020;382(22):2081-2090.
Janus SIM, Schepel AAM, Zuidema SU, de Haas EC. How Typical is the Spectrum of COVID-19 in Nursing Home Residents? J Am Med Dir Assoc 2020;22(3):511-513.e3.
Gil-Rodrigo A, Miró Ò, Piñera P et al. Evaluación de las características clínicas y evolución de pacientes con COVID-19 a partir de una serie de 1.000 pacientes
atendidos en servicios de urgencias españoles. Emergencias. 2020;32(4):233-241.
Dixon BE, Wools-Kaloustian K, Fadel WF et al. Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study. Preprint. medRxiv. 2020;2020.10.11.20210922.
Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: : A Systematic Review. Ann Intern Med. 2021;M20-6976.
Pollán M, Pérez-Gómez B, Pastor-Barriuso R et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535-544.
Mikami T, Miyashita H, Yamada T et al. Risk Factors for Mortality in Patients with COVID-19 in New York City. J Gen Intern Med. 2021;36(1):17-26.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Ángel Vila-Córcoles, Ángel Vila-Rovira, Eva María Satué-Gracia, Olga Ochoa-Gondar, Cinta de Diego-Cabanes, Immaculada Hospital-Guardiola, María José Forcadell-Peris, Francisco Martín-Luján, Josep Basora-Gallisà
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
